Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes

Rhabdoid tumors (RTs) are aggressive tumors of early childhood that occur most often in brain (AT/RTs) or kidney (KRTs). Regardless of location, they are characterized by loss of functional SMARCB1 protein, a component of the SWI/SNF chromatin remodeling complex. The aim of this study was to determine genes and biological process dysregulated in common to both AT/RTs and KRTs.

[1]  P. Northcott,et al.  Targeting the enhancer of zeste homologue 2 in medulloblastoma , 2012, International journal of cancer.

[2]  J. Biegel,et al.  Novel cell lines established from pediatric brain tumors , 2012, Journal of Neuro-Oncology.

[3]  R. Vibhakar,et al.  Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. , 2012, Neuro-oncology.

[4]  R. Vibhakar,et al.  Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells , 2012, Journal of Neuro-Oncology.

[5]  B. Kleinschmidt-DeMasters,et al.  High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. , 2011, Neuro-oncology.

[6]  M. Rosenblum,et al.  Atypical Teratoid/Rhabdoid Tumor Arising in a Ganglioglioma: Genetic Characterization , 2011, The American journal of surgical pathology.

[7]  L. Sullivan,et al.  Malignant Rhabdoid Tumors Express Stem Cell Factors, Which Relate To the Expression of EZH2 and Id Proteins , 2011, The American journal of surgical pathology.

[8]  J. Biegel,et al.  p16INK4A and p14ARF Tumor Suppressor Pathways Are Deregulated in Malignant Rhabdoid Tumors , 2011, Journal of neuropathology and experimental neurology.

[9]  Scott L Pomeroy,et al.  Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. , 2010, Cancer cell.

[10]  P. Schirmacher,et al.  Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma , 2010, BMC Cancer.

[11]  E. Hurt,et al.  Clinical significance of Polycomb gene expression in brain tumors , 2010, Molecular Cancer.

[12]  J. Biegel,et al.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.

[13]  M. Garrè,et al.  Role of high‐dose chemotherapy (HDCT) in treatment of atypical teratoid/rhabdoid tumors (AT/RTs) , 2010, Pediatric blood & cancer.

[14]  Chiang-Ching Huang,et al.  Rhabdoid Tumor: Gene Expression Clues to Pathogenesis and Potential Therapeutic Targets , 2010, Laboratory Investigation.

[15]  K. Shin‐ya,et al.  Disabling c-Myc in Childhood Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor Cells by the Potent G-Quadruplex Interactive Agent S2T1-6OTD , 2010, Molecular Cancer Therapeutics.

[16]  J. Biegel,et al.  Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors , 2009, PloS one.

[17]  J. Biegel,et al.  Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Verrijzer,et al.  SWI/SNF Mediates Polycomb Eviction and Epigenetic Reprogramming of the INK4b-ARF-INK4a Locus , 2008, Molecular and Cellular Biology.

[19]  D. Zagzag,et al.  INI1 Induces Interferon Signaling and Spindle Checkpoint in Rhabdoid Tumors , 2007, Clinical Cancer Research.

[20]  C. Lanvers-Kaminsky,et al.  Inhibitors of histone deacetylases as potential therapeutic tools for high‐risk embryonal tumors of the nervous system of childhood , 2007, International journal of cancer.

[21]  J. Biegel,et al.  Atypical teratoid/rhabdoid tumor arising in the setting of a pleomorphic xanthoastrocytoma , 2007, Journal of Neuro-Oncology.

[22]  O. Delattre,et al.  The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells. , 2006, European journal of cancer.

[23]  P. Houghton,et al.  Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo , 2006, Clinical Cancer Research.

[24]  Pablo Tamayo,et al.  Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Weissman,et al.  Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. , 2005, Cancer research.

[26]  B. Scheithauer,et al.  Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  O. Delattre,et al.  The Tumor Suppressor hSNF5/INI1 Modulates Cell Growth and Actin Cytoskeleton Organization , 2004, Cancer Research.

[28]  J. Biegel,et al.  Immunohistochemical Analysis of hSNF5/INI1 in Pediatric CNS Neoplasms , 2004, The American journal of surgical pathology.

[29]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[30]  S. Bates,et al.  MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. , 2002, Cancer research.

[31]  J. Biegel,et al.  Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  Liang Zhu,et al.  Cell Cycle Arrest and Repression of Cyclin D1 Transcription by INI1/hSNF5 , 2002, Molecular and Cellular Biology.

[33]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[34]  Guang-Yuh Chiou,et al.  Differential expression profiling between atypical teratoid/rhabdoid and medulloblastoma tumor in vitro and in vivo using microarray analysis , 2009, Child's Nervous System.

[35]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[36]  M. Rosenblum,et al.  Atypical teratoid/rhabdoid tumor evolving from an optic pathway ganglioglioma: case study. , 2006, Neuro-oncology.

[37]  Anushya Muruganujan,et al.  PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification , 2003, Nucleic Acids Res..